TD Cowen: 'CABA appears well-positioned to scale commercially with minimal capital investment'

August 13, 2026 10:32 AM

TD Cowen analyst Phil Nadeau reiterated a Buy rating on Cabaletta Bio (NASDAQ: CABA).The analyst comments "Cabaletta continues to execute ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found